» Articles » PMID: 35281899

Recent Advances in Traditional Chinese Medicine for Treatment of Podocyte Injury

Overview
Journal Front Pharmacol
Date 2022 Mar 14
PMID 35281899
Authors
Affiliations
Soon will be listed here.
Abstract

Podocyte is also called glomerular epithelial cell, which has been considered as the final gatekeeper of glomerular filtration barrier (GFB). As a major contributor to proteinuria, podocyte injury underlies a variety of glomerular diseases and becomes the challenge to patients and their families in general. At present, the therapeutic methods of podocyte injury mainly include angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, steroid and immunosuppressive medications. Nevertheless, the higher cost and side effects seriously disturb patients with podocyte injury. Promisingly, traditional Chinese medicine (TCM) has received an increasing amount of attention from different countries in the treatment of podocyte injury by invigorating spleen and kidney, clearing heat and eliminating dampness, as well enriching qi and activating blood. Therefore, we searched articles published in peer-reviewed English-language journals through Google Scholar, PubMed, Web of Science, and Science Direct. The protective effects of active ingredients, herbs, compound prescriptions, acupuncture and moxibustion for treatment of podocyte injury were further summarized and analyzed. Meanwhile, we discussed feasible directions for future development, and analyzed existing deficiencies and shortcomings of TCM in the treatment of podocyte injury. In conclusion, this paper shows that TCM treatments can serve as promising auxiliary therapeutic methods for the treatment of podocyte injury.

Citing Articles

Therapeutic potential of -based Eefooton in patients with chronic kidney disease: from clinical to bench study.

Lu K, Kuo K, Wu S, Lin C, Lin C, Hou Y Int J Med Sci. 2025; 22(1):227-239.

PMID: 39744164 PMC: 11659832. DOI: 10.7150/ijms.102280.


Exploring the therapeutic mechanism of Yuebi decoction on nephrotic syndrome based on network pharmacology and experimental study.

Yao T, Wang Q, Han S, Xu Y, Chen M, Wang Y Aging (Albany NY). 2024; 16(18):12623-12650.

PMID: 39311772 PMC: 11466484. DOI: 10.18632/aging.206116.


A simple protocol to establish a conditionally immortalized mouse podocyte cell line.

Huang Y, Geng J, Wang M, Liu W, Hu H, Shi W Sci Rep. 2024; 14(1):11591.

PMID: 38773220 PMC: 11109129. DOI: 10.1038/s41598-024-62547-5.


Therapeutic potential of artemisinin and its derivatives in managing kidney diseases.

Jin Q, Liu T, Chen D, Yang L, Mao H, Ma F Front Pharmacol. 2023; 14:1097206.

PMID: 36874000 PMC: 9974673. DOI: 10.3389/fphar.2023.1097206.

References
1.
Kunnumakkara A, Harsha C, Banik K, Vikkurthi R, Sailo B, Bordoloi D . Is curcumin bioavailability a problem in humans: lessons from clinical trials. Expert Opin Drug Metab Toxicol. 2019; 15(9):705-733. DOI: 10.1080/17425255.2019.1650914. View

2.
He L, Zhao R, Wang Y, Liu H, Wang X . Research Progress on Catalpol as Treatment for Atherosclerosis. Front Pharmacol. 2021; 12:716125. PMC: 8313760. DOI: 10.3389/fphar.2021.716125. View

3.
Zhang M, Liu M, Xiong M, Gong J, Tan X . Schisandra chinensis fruit extract attenuates albuminuria and protects podocyte integrity in a mouse model of streptozotocin-induced diabetic nephropathy. J Ethnopharmacol. 2012; 141(1):111-8. DOI: 10.1016/j.jep.2012.02.007. View

4.
Chen Y, Liu Q, Shan Z, Mi W, Zhao Y, Li M . Catalpol Ameliorates Podocyte Injury by Stabilizing Cytoskeleton and Enhancing Autophagy in Diabetic Nephropathy. Front Pharmacol. 2020; 10:1477. PMC: 6914850. DOI: 10.3389/fphar.2019.01477. View

5.
Yu S, Nissaisorakarn P, Husain I, Jim B . Proteinuric Kidney Diseases: A Podocyte's Slit Diaphragm and Cytoskeleton Approach. Front Med (Lausanne). 2018; 5:221. PMC: 6141722. DOI: 10.3389/fmed.2018.00221. View